Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-10,316,393
Closed -$152M 5564
2025
Q3
$152M Sell
10,316,393
-253,031
-2% -$2.58M ﹤0.01% 1832
2025
Q2
$104M Buy
10,569,424
+494,080
+5% +$4.09M ﹤0.01% 2021
2025
Q1
$73.2M Buy
10,075,344
+2,185,245
+28% +$19.1M ﹤0.01% 2177
2024
Q4
$61.7M Buy
7,890,099
+340,797
+5% +$2.81M ﹤0.01% 2330
2024
Q3
$55.9M Buy
7,549,302
+533,727
+8% +$4.49M ﹤0.01% 2407
2024
Q2
$56.2M Buy
7,015,575
+377,591
+6% +$3.37M ﹤0.01% 2343
2024
Q1
$77.3M Buy
6,637,984
+1,183,788
+22% +$13.1M ﹤0.01% 2206
2023
Q4
$60.9M Buy
5,454,196
+487,956
+10% +$4.49M ﹤0.01% 2354
2023
Q3
$76.7M Buy
4,966,240
+316,057
+7% +$5.31M ﹤0.01% 2145
2023
Q2
$88.1M Buy
4,650,183
+3,400,611
+272% +$59.7M ﹤0.01% 2127
2023
Q1
$19M Buy
1,249,572
+179,991
+17% +$2.35M ﹤0.01% 3003
2022
Q4
$13.6M Buy
1,069,581
+159,539
+18% +$1.44M ﹤0.01% 3240
2022
Q3
$5.27M Buy
910,042
+382,677
+73% +$1.68M ﹤0.01% 3730
2022
Q2
$1.7M Sell
527,365
-394,865
-43% -$1.19M ﹤0.01% 4315
2022
Q1
$3.48M Buy
922,230
+70,489
+8% +$454K ﹤0.01% 4142
2021
Q4
$11.1M Buy
851,741
+119,347
+16% +$1.89M ﹤0.01% 3609
2021
Q3
$14.3M Sell
732,394
-7,209
-1% -$132K ﹤0.01% 3492
2021
Q2
$13.8M Buy
739,603
+38,111
+5% +$851K ﹤0.01% 3518
2021
Q1
$16.6M Buy
701,492
+42,659
+6% +$985K ﹤0.01% 3283
2020
Q4
$16.1M Buy
658,833
+223,147
+51% +$5.7M ﹤0.01% 3125
2020
Q3
$11.2M Buy
435,686
+221,709
+104% +$7.03M ﹤0.01% 3163
2020
Q2
$4.26M Sell
213,977
-3,771
-2% -$91.7K ﹤0.01% 3587
2020
Q1
$5.5M Buy
217,748
+34,426
+19% +$1.01M ﹤0.01% 3315
2019
Q4
$4.82M Buy
+183,322
New +$5.1M ﹤0.01% 3512

Other funds holding ETNB

BlackRock's ETNB Position: Q4 2025 in Review

BlackRock sold out of 89bio (ETNB) in Q4 2025, closing a stake of 10,316,393 shares — an estimated $152M sold.

BlackRock first reported a position in ETNB in Q4 2019 and held it in 24 quarters. The position peaked at $152M in Q3 2025. 2 funds tracked by Wall St. Rank hold ETNB as of Q4 2025.

  • BlackRock reported no remaining 89bio position as of Q4 2025 after selling out during the quarter.
  • BlackRock sold 10,316,393 89bio shares in Q4 2025, an estimated $152M.
  • BlackRock first reported a position in 89bio in Q4 2019 and held it in 24 quarters.
  • BlackRock's 89bio position peaked at $152M in Q3 2025.
  • 2 funds tracked by Wall St. Rank held 89bio as of Q4 2025.

Based on BlackRock's 13F filing for Q4 2025, filed 12 Feb 2026.